Q-omics provides the consensus-scored HMX2 profile across patient tissues and cancer cell-line models. HMX2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HMX2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, HMX2 RNA expression shows 10,741 significant mutation-linked associations, with the highest sampling consensus in UCEC. Together, these results highlight ACC, KIRC, and UCEC as cancer lineages where HMX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMX2 survival associations across molecular data types. HMX2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMX2 RNA expression–survival associations across cancer types. High HMX2 expression shows unfavorable associations in ACC, MESO, THCA and LAML, but favorable associations in HNSC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for HMX2 RNA expression.
This table summarizes HMX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HMX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMX2 shows lower tumor expression in KIRC, KIRP, COAD and KICH and higher tumor expression in UCEC and HNSC. The KIRC box plot shows higher HMX2 RNA expression in normal versus tumor tissue (log2 FC = −1.940, t-test p < 0.001).
This table shows molecular features associated with HMX2 in patient tissues and cancer cell lines. In patient samples, HMX2 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set. In cancer cell lines, HMX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
